Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q2 2022
Holdings as of Jun 30, 2022, filed Aug 15, 2022. Long positions only; changes compare share counts with Q1 2022.
- Positions
- 29
- −10 vs. Q1 2022
- Portfolio value
- $145.5M
- −$56.4M (−27.9%) vs. Q1 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 1,900 | $277.0K | 0.2% | +1,900 | New | History |
| DICEDICE Therapeutics, Inc. | COM | 30,000 | $466.0K | 0.3% | +30,000 | New | History |
| SYRESpyre Therapeutics, Inc. | COM | 925,000 | $467.0K | 0.3% | +238,401+34.7% | Added | History |
| NMTR9 Meters Biopharma, Inc. | COM | 1,800,000 | $469.0K | 0.3% | −1,450,000−44.6% | Reduced | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 300,000 | $1.57M | 1.1% | +300,000 | New | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 120,000 | $1.75M | 1.2% | 00.0% | Unchanged | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 150,000 | $1.85M | 1.3% | 00.0% | Unchanged | History |
| RAPTRAPT Therapeutics, Inc. | COM | 165,000 | $3.01M | 2.1% | −85,000−34.0% | Reduced | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 325,000 | $3.44M | 2.4% | −25,000−7.1% | Reduced | History |
| KZRKezar Life Sciences, Inc. | COM | 450,000 | $3.72M | 2.6% | +50,000+12.5% | Added | History |
| DSGNDesign Therapeutics, Inc. | COM | 275,000 | $3.85M | 2.6% | +75,000+37.5% | Added | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 225,000 | $4.33M | 3.0% | 00.0% | Unchanged | History |
| ARVNArvinas, Inc. | COM | 110,000 | $4.63M | 3.2% | 00.0% | Unchanged | History |
| RLMDRelmada Therapeutics, Inc. | COM | 250,000 | $4.75M | 3.3% | +150,000+150.0% | Added | History |
| CTICCti Biopharma Corp | COM | 800,000 | $4.78M | 3.3% | −500,000−38.5% | Reduced | History |
| ISEEIVERIC bio, Inc. | COM | 500,000 | $4.81M | 3.3% | +50,000+11.1% | Added | History |
| MRUSMerus N.V. | COM | 250,000 | $5.66M | 3.9% | −150,000−37.5% | Reduced | History |
| KRTXKaruna Therapeutics, Inc. | COM | 45,000 | $5.69M | 3.9% | −15,000−25.0% | Reduced | History |
| SGENSeagen Inc. | COM | 35,000 | $6.19M | 4.3% | +35,000 | New | History |
| VRDNViridian Therapeutics, Inc. | COM | 600,000 | $6.94M | 4.8% | +133,597+28.6% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 75,000 | $6.97M | 4.8% | −65,000−46.4% | Reduced | History |
| PCVXVaxcyte, Inc. | COM | 325,000 | $7.07M | 4.9% | +25,000+8.3% | Added | History |
| MRTXMirati Therapeutics, Inc. | COM | 110,000 | $7.38M | 5.1% | +90,000+450.0% | Added | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 100,000 | $7.98M | 5.5% | +100,000 | New | History |
| COGTCogent Biosciences, Inc. | COM | 900,000 | $8.12M | 5.6% | −800,000−47.1% | Reduced | History |
| AXSMAxsome Therapeutics, Inc. | COM | 225,000 | $8.62M | 5.9% | +130,500+138.1% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 130,000 | $9.74M | 6.7% | +80,000+160.0% | Added | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 225,000 | $10.2M | 7.0% | −25,000−10.0% | Reduced | History |
| FOLDAmicus Therapeutics, Inc. | COM | 1,000,000 | $10.7M | 7.4% | −100,000−9.1% | Reduced | History |
Options (3)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q1 2022 (15)
Positions held at the end of Q1 2022 that are gone from this filing.
| Security | Class | Shares in Q1 2022 | Value in Q1 2022 | % of portfolio in Q1 2022 | History |
|---|---|---|---|---|---|
| SRRASierra Oncology, Inc. | COM NEW | 325,000 | $10.4M | 5.2% | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 300,000 | $10.2M | 5.1% | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 100,000 | $4.39M | 2.2% | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 750,000 | $3.74M | 1.9% | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 80,000 | $3.69M | 1.8% | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 200,000 | $3.17M | 1.6% | History |
| XENEXenon Pharmaceuticals Inc. | COM | 100,000 | $3.06M | 1.5% | History |
| ACRSAclaris Therapeutics, Inc. | COM | 125,000 | $2.15M | 1.1% | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 85,000 | $1.87M | 0.9% | History |
| STSASatsuma Pharmaceuticals, Inc. | COM | 473,562 | $1.80M | 0.9% | History |
| CYPHCypherpunk Technologies Inc. | COM | 993,714 | $1.74M | 0.9% | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 1,315,154 | $1.63M | 0.8% | History |
| PRDSPardes Biosciences, Inc. | COM | 85,000 | $614.0K | 0.3% | History |
| LRMRLarimar Therapeutics, Inc. | COM | 100,000 | $405.0K | 0.2% | History |
| PYXSPyxis Oncology, Inc. | COMMON STOCK | 75,000 | $303.0K | 0.2% | History |